2018 AANS Annual Scientific Meeting-Oncolytic HSV and Immunotherapy for Adults and Children with Glioma

Oncolytic HSV and Immunotherapy for Adults and Children with Glioma

Video Transcription

Video Summary

In the video, Jim Markert discusses his experiments at the University of Alabama with Oncolytic HSV immunotherapy for adults and children. He mentions different versions of the virus that have been used in clinical trials, such as GTO7, 1716, M032, RQNestin 34.5 version 2, G47 Delta, and C134. He also talks about the success of Imligec or TVEC, a similar therapy approved by the FDA for melanoma. Markert then focuses on his own studies with G207 and M032 in adults and children, highlighting some positive responses observed in patients, including tumor necrosis and immune response. He also mentions ongoing trials with M032 in canines and the development of C134 as a potential next-generation virus. Markert believes that combining immunotherapeutic agents with oncolytic viruses could hold promise for treating glioblastoma, but emphasizes the need for further research and optimal treatment timing.

Asset Caption

James M. Markert Jr., MD, FAANS

Keywords

Oncolytic HSV immunotherapy

clinical trials

G207

tumor necrosis

immune response